Compare BIO-TECHNE Corp (TECH) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Health Care Select Sector SPDR Fund — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Health Care Select Sector SPDR Fund trades at $167.94. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| TECH | XLV | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | — |
52-Week High | $72.29 | $168.44 |
52-Week Low | $43.31 | $131.16 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
XLV trades at $165.68, up 0.75% with a bullish technical signal from moving averages. The healthcare ETF shows strong defensive positioning amid market volatility, with recent articles highlighting its cost efficiency at 0.08% expense ratio and $41.7 billion AUM. Technical indicators show support at $164 and resistance at $167, with RSI levels in neutral territory suggesting balanced momentum.
The outlook remains positive given healthcare's defensive characteristics and recent sector inflows. Key risks include regulatory pressures and competitive ETF offerings, but XLV's diversification across 60 healthcare stocks provides stability. Analyst comparisons favor XLV for lower costs and steady performance versus specialized biotech ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
